本文選題：厄洛替尼 + 皮疹�。� 參考：《中國比較醫(yī)學(xué)雜志》2017年01期

【摘要】：目的厄洛替尼(商品名:特羅凱)是治療非小細(xì)胞肺癌的一種新型靶向藥物,近些年來臨床應(yīng)用甚廣,但副作用較多,其中以皮疹最為多見,且最令患者難以接受。本研究旨在觀察應(yīng)用特羅凱前后小鼠在表皮、病理、免疫組化等方面的改變,復(fù)制特羅凱所致皮疹的動(dòng)物模型,為臨床外用藥物治療皮疹提供模型。方法使用BALB/c雌性小鼠20只,隨機(jī)分成4組。實(shí)驗(yàn)組(Ⅱ、Ⅲ、Ⅳ組)用濃度為10 g/L的特羅凱溶液按100 mg/kg灌胃,對(duì)照組(Ⅰ組)以等體積去離子水灌胃,每天1次。于給藥前24 h在小鼠頭頸、背、腰處脫毛,實(shí)驗(yàn)結(jié)束后剪取頸部、背部、腰部皮膚并觀察實(shí)驗(yàn)組、對(duì)照組小鼠在肉眼皮膚、病理切片、免疫組化等方面的改變。結(jié)果 (1)四組小鼠之間在毛發(fā)再生天數(shù)、毛發(fā)完全再生天數(shù)、脫屑時(shí)間、出現(xiàn)皮疹時(shí)間、毛孔擴(kuò)張數(shù)等5方面的差異存在統(tǒng)計(jì)學(xué)意義(P0.01或P0.05);(2)Ki67:四組間差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論 (1)此次實(shí)驗(yàn)印證了許多研究者關(guān)于"EGFRIs導(dǎo)致的皮疹為一種炎癥反應(yīng)"的觀點(diǎn);(2)該皮疹模型可靠實(shí)用,具有可重復(fù)性,適用于"EGFRIs所致皮疹動(dòng)物模型"的大批建立,可推廣以供臨床、試驗(yàn)、研究所用。
[Abstract]:Objective erlotinib (trade name: trokei) is a new target drug for the treatment of non-small cell lung cancer (NSCLC). In recent years, it is widely used in clinical practice, but has many side effects, among which rash is the most common and most difficult for patients to accept.The purpose of this study was to observe the changes of epidermis, pathology and immunohistochemistry in mice before and after troke-induced skin rash, and to establish the animal model of the skin rash induced by troke-induced skin rash, and to provide a model for the treatment of skin rash by external medicine.Methods Twenty BALB/c female mice were randomly divided into 4 groups.The experimental group (group 鈪，

本文編號(hào)：1739624